United Laboratories International Holdings
Market Cap
HK$9.2b
Last Updated
2020/01/22 12:50 UTC
Data Sources
Company Financials +
Executive Summary
The United Laboratories International Holdings Limited, an investment holding company, manufactures and sells pharmaceutical products.
Rewards
Risk Analysis
Snowflake Analysis
Solid track record and good value.
Share Price & News
How has United Laboratories International Holdings's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: 3933 has not had significant price volatility in the past 3 months.
Market Performance
7 Day Return
1.8%
3933
8.2%
HK Pharmaceuticals
-1.4%
HK Market
1 Year Return
29.7%
3933
20.1%
HK Pharmaceuticals
3.5%
HK Market
Return vs Industry: 3933 exceeded the Hong Kong Pharmaceuticals industry which returned 17% over the past year.
Return vs Market: 3933 exceeded the Hong Kong Market which returned 6.4% over the past year.
Shareholder returns
| 3933 | Industry | Market | |
|---|---|---|---|
| 7 Day | 1.8% | 8.2% | -1.4% |
| 30 Day | 1.1% | 11.1% | 1.8% |
| 90 Day | 29.1% | 11.6% | 6.0% |
| 1 Year | 32.0%29.7% | 22.5%20.1% | 7.3%3.5% |
| 3 Year | 23.9%20.9% | 58.5%50.9% | 23.3%10.8% |
| 5 Year | 47.6%44.1% | 49.1%36.9% | 19.2%-0.7% |
Price Volatility Vs. Market
How volatile is United Laboratories International Holdings's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 day ago | Simply Wall St
Is The United Laboratories International Holdings Limited (HKG:3933) A Smart Pick For Income Investors?2 weeks ago | Simply Wall St
Have Insiders Been Selling The United Laboratories International Holdings Limited (HKG:3933) Shares This Year?1 month ago | Simply Wall St
United Laboratories International Holdings (HKG:3933) Has A Somewhat Strained Balance SheetValuation
Is United Laboratories International Holdings undervalued compared to its fair value and its price relative to the market?
>50%
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: 3933 (HK$5.62) is trading below our estimate of fair value (HK$13.15)
Significantly Below Fair Value: 3933 is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: 3933 is good value based on its PE Ratio (9.2x) compared to the Pharmaceuticals industry average (11.6x).
PE vs Market: 3933 is good value based on its PE Ratio (9.2x) compared to the Hong Kong market (10.5x).
Price to Earnings Growth Ratio
PEG Ratio: 3933 is poor value based on its PEG Ratio (1x)
Price to Book Ratio
PB vs Industry: 3933 is overvalued based on its PB Ratio (1.3x) compared to the HK Pharmaceuticals industry average (1.2x).
Next Steps
Future Growth
How is United Laboratories International Holdings forecast to perform in the next 1 to 3 years based on estimates from 7 analysts?
9.1%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 3933's forecast earnings growth (9.1% per year) is above the savings rate (1.6%).
Earnings vs Market: 3933's earnings (9.1% per year) are forecast to grow slower than the Hong Kong market (11.3% per year).
High Growth Earnings: 3933's earnings are forecast to grow, but not significantly.
Revenue vs Market: 3933's revenue (6.1% per year) is forecast to grow slower than the Hong Kong market (10.2% per year).
High Growth Revenue: 3933's revenue (6.1% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 3933's Return on Equity is forecast to be low in 3 years time (9.9%).
Next Steps
Past Performance
How has United Laboratories International Holdings performed over the past 5 years?
8.6%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 3933 has high quality earnings.
Growing Profit Margin: 3933's current net profit margins (11.4%) are higher than last year (0.9%).
Past Earnings Growth Analysis
Earnings Trend: 3933's earnings have grown by 8.6% per year over the past 5 years.
Accelerating Growth: 3933's earnings growth over the past year (1291.2%) exceeds its 5-year average (8.6% per year).
Earnings vs Industry: 3933 earnings growth over the past year (1291.2%) exceeded the Pharmaceuticals industry 23%.
Return on Equity
High ROE: 3933's Return on Equity (14%) is considered low.
Return on Assets
Return on Capital Employed
Next Steps
Financial Health
How is United Laboratories International Holdings's financial position?
Financial Position Analysis
Short Term Liabilities: 3933's short term assets (CN¥7.6B) do not cover its short term liabilities (CN¥8.0B).
Long Term Liabilities: 3933's short term assets (CN¥7.6B) exceed its long term liabilities (CN¥936.4M).
Debt to Equity History and Analysis
Debt Level: 3933's debt to equity ratio (70.1%) is considered high.
Reducing Debt: 3933's debt to equity ratio has reduced from 90.6% to 70.1% over the past 5 years.
Debt Coverage: 3933's debt is well covered by operating cash flow (32.4%).
Interest Coverage: 3933's interest payments on its debt are well covered by EBIT (3.4x coverage).
Balance Sheet
Inventory Level: 3933 has a high level of physical assets or inventory.
Debt Coverage by Assets: 3933's debt is covered by short term assets (assets are 1.7x debt).
Next Steps
Dividend
What is United Laboratories International Holdings's current dividend yield, its reliability and sustainability?
1.18%
Current Dividend Yield
Dividend Yield vs Market
Current dividend yield vs market & industry
Notable Dividend: 3933's dividend (1.2%) isn’t notable compared to the bottom 25% of dividend payers in the Hong Kong market (2.17%).
High Dividend: 3933's dividend (1.2%) is low compared to the top 25% of dividend payers in the Hong Kong market (6.02%).
Stability and Growth of Payments
Stable Dividend: 3933 is not paying a notable dividend for the Hong Kong market, therefore no need to check if payments are stable.
Growing Dividend: 3933 is not paying a notable dividend for the Hong Kong market, therefore no need to check if payments are increasing.
Current Payout to Shareholders
Dividend Coverage: 3933 is not paying a notable dividend for the Hong Kong market.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of 3933's dividend in 3 years as they are not forecast to pay a notable one for the Hong Kong market.
Next Steps
Management
What is the CEO of United Laboratories International Holdings's salary, the management and board of directors tenure and is there insider trading?
9.2yrs
Average board tenure
CEO
United Laboratories International Holdings has no CEO, or we have no data on them.
Board Age and Tenure
9.2yrs
Average Tenure
54yo
Average Age
Experienced Board: 3933's board of directors are considered experienced (9.2 years average tenure).
Insider Trading
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
| Entity | Individual |
| Role | Member of the Board of Directors Global Director of Intermediate & Bulk Medicine and Executive Director |
| Shares | 1,110,000 |
| Max Price | HK$4.31 |
| Entity | Individual |
| Role | Member of the Board of Directors Global Director of Intermediate & Bulk Medicine and Executive Director |
| Shares | 3,400,000 |
| Max Price | HK$4.38 |
| Entity | Company |
| Shares | 3,034,000 |
| Max Price | HK$5.16 |
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Management Team
Su Yan Zhu (54yo)
VP & Executive Director
- Tenure: 9.2yrs
- Compensation: CN¥2.28m
Xian Hong Zou (54yo)
VP & Executive Director
- Tenure: 9.2yrs
- Compensation: CN¥2.26m
Shou Wu (52yo)
Head of Production Plant -Zhongshan
Siu Chit Choy (46yo)
Global Director of Intermediate & Bulk Medicine and Executive Director
- Tenure: 6.6yrs
- Compensation: CN¥3.07m
Wing Hon Leung (57yo)
Vice Chairman
- Tenure: 6.8yrs
- Compensation: CN¥3.17m
Hoi Shan Tsoi (41yo)
Executive Chairman
- Tenure: 6.8yrs
- Compensation: CN¥3.27m
Yu Ping Fang (56yo)
VP, GM of China Sales Division & Executive Director
- Tenure: 9.2yrs
- Compensation: CN¥2.28m
Board Members
Su Yan Zhu (54yo)
VP & Executive Director
- Tenure: 9.2yrs
- Compensation: CN¥2.28m
Ming Song (57yo)
Independent Non-Executive Director
- Tenure: 12.7yrs
- Compensation: CN¥204.00k
Xian Hong Zou (54yo)
VP & Executive Director
- Tenure: 9.2yrs
- Compensation: CN¥2.26m
Siu Chit Choy (46yo)
Global Director of Intermediate & Bulk Medicine and Executive Director
- Tenure: 6.6yrs
- Compensation: CN¥3.07m
Wing Hon Leung (57yo)
Vice Chairman
- Tenure: 6.8yrs
- Compensation: CN¥3.17m
Hoi Shan Tsoi (41yo)
Executive Chairman
- Tenure: 6.8yrs
- Compensation: CN¥3.27m
Peng Oon Chong (70yo)
Independent Non-Executive Director
- Tenure: 10.8yrs
- Compensation: CN¥204.00k
Yu Ping Fang (56yo)
VP, GM of China Sales Division & Executive Director
- Tenure: 9.2yrs
- Compensation: CN¥2.28m
Xiao Nan Fu (49yo)
Independent Non-Executive Director
- Tenure: 7.1yrs
- Compensation: CN¥204.00k
Company Information
The United Laboratories International Holdings Limited's company bio, employee growth, exchange listings and data sources
Key Information
- Name: The United Laboratories International Holdings Limited
- Ticker: 3933
- Exchange: SEHK
- Founded: 1990
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: HK$9.159b
- Shares outstanding: 1.64b
- Website: https://www.tul.com.cn
Number of Employees
Location
- The United Laboratories International Holdings Limited
- 6 Fuk Wang Street
- Yuen Long Industrial Estate
- Yuen Long
- New Territories
- Hong Kong
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| 3933 | SEHK (The Stock Exchange of Hong Kong Ltd.) | Yes | Ordinary Shares | HK | HKD | Jun 2007 |
| UNJ | DB (Deutsche Boerse AG) | Yes | Ordinary Shares | DE | EUR | Jun 2007 |
| ULIH.F | OTCPK (Pink Sheets LLC) | Yes | Ordinary Shares | US | USD | Jun 2007 |
| 3933 | SZSC (The Stock Exchange of Hong Kong - Shenzhen - Hong Kong Stock Connect) | Yes | Ordinary Shares | HK | HKD | Jun 2007 |
Biography
The United Laboratories International Holdings Limited, an investment holding company, manufactures and sells pharmaceutical products. It operates in three segments: Intermediate Products, Bulk Medicine, and Finished Products. The company offers oral antibiotics, antimicrobials for injection, anti-cold products, cough medicines, ophthalmic drugs, antiviral drugs, anti-hepatitis B drugs, diabetes drugs, skin drugs for external use, cardiovascular and cerebrovascular drugs, nervous system drugs, vitamins, and vacant gelatin capsules, as well as non-antibiotics finished products and soft capsule casings. It also provides chemical pharmaceuticals and food products. In addition, the company manufactures and sells organic fertilizers; holds trademarks; trades in pharmaceutical products; and offers management services. It has operations in the People's Republic of China, Europe, India, Hong Kong, the Middle East, South America, other Asian regions, and other regions. The company was founded in 1990 and is headquartered in Yuen Long, Hong Kong. The United Laboratories International Holdings Limited is a subsidiary of Heren Far East Limited.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2020/01/22 12:50 |
| End of Day Share Price | 2020/01/22 00:00 |
| Earnings | 2019/06/30 |
| Annual Earnings | 2018/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.